TP53 and neoplasm: BRCA1/p53 double-deficient tumor cells are prone to increased replication stress and DSBs [10], which could explain, at least partly, the role of EZH2 inhibition as sensitizer to ATM inhibition (this manuscript) and cisplatin [14].